4.3 Article

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e3181e9be6b

Keywords

AIDS-defining illnesses; CD4; HIV; morbidity; mortality; non-AIDS-defining illnesses

Funding

  1. European Commission [CT94-1637, CT97-2713, QLK2-2000-00773, LSHP-CT-2006-018632]
  2. Gilead
  3. Pfizer
  4. Merck and Co.
  5. Swiss Federal Office for Education and Science

Ask authors/readers for more resources

Background: Little is known about the incidence and risk factors for serious non-AIDS-defining events. Methods: The incidence of non-AIDS events (malignancies, end-stage renal disease, liver failure, pancreatitis, cardiovascular disease), and AIDS after January 1, 2001, was calculated; Poisson regression was used to investigate factors associated with non-AIDS and AIDS. Results: Among 12,844 patients, 1058 were diagnosed with a non-AIDS event [incidence 1.77 per 100 person-years of follow-up; 95% confidence interval (CI): 1.66 to 1.87]; 462 patients (43.7%) died. The incidence of AIDS (1025 diagnoses; 339 deaths, 33.1%) was 1.72 per 100 person-years of follow-up (1.61 to 1.83). After adjustment, older age [incidence rate ratio (IRR): 1.71 per 10 years older, 95% CI: 1.60 to 1.83], diabetes (IRR: 1.49, 95% CI: 1.22 to 1.82) and hypertension (IRR: 1.63, 95% CI: 1.43 to 1.87) were associated with non-AIDS events. Compared with patients without an event, there was a 4-fold increased risk of death after an AIDS event (relative hazard: 4.14; 95% CI 3.47 to 4.94) and almost a 7-fold increased risk of death after a non-AIDS event (relative hazard: 6.72; 95% CI: 5.61 to 8.05). Conclusions: Non-AIDS events were common in the combination antiretroviral therapy era and associated with considerably mortality. Evidence on the impact of modifying immunodeficiency and lifestyle-related factors on the risk of non-AIDS events in HIV-infected persons is an important but unmet research need.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available